Evidence map›Paper›PMID 16160173›Full record

ArticleJournal of virology2005

Virion envelope content, infectivity, and neutralization sensitivity of simian immunodeficiency virus.

Eloísa Yuste, Welkin Johnson, George N Pavlakis, Ronald C Desrosiers

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
1.6field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. In vivo evolution of env in SHIV-AD8Molecular therapy : the journal of the American Society of Gene Therapy · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. HIV envelope tail truncation confers resistance to SERINC5 restriction.Proceedings of the National Academy of Sciences of the United States of America · 2021
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Vaccine protection against SIVmac239 acquisition.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Eloísa YusteNew England Primate Research Center, Department of Microbiology and Molecular Genetics, Harvard Medical School, Southborough, MA 01772-9102, USA.
Welkin Johnson
George N Pavlakis
Ronald C Desrosiers
New England Biolabs (United States) · USCenter for Cancer Research · US

Funding

ZETA CHAIN OF T CELL RECEPTOR INTERACTS W/ NEF OF SIV &HIV2P51RR000168 · NCRR · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JOHNSON, R. PAUL · 1985 to 2011
$139.3M
Replication and Persistence of Primate LentivirusesR01AI057039 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JOHNSON, WELKIN E · 2003 to 2009
$1.9M
Contributions of HIV qp41 TM Protein to PathogenesisR01AI050421 · NIAID · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI DESROSIERS, RONALD C · 2001 to 2005
$1.9M
HIV Molecular Biology and Pathogenic Mechanisms of AIDSZ01BC010750 · NCI · DIVISION OF BASIC SCIENCES - NCI · PI PAVLAKIS, GEORGE N. · 2006 to 2008
$919k
MOUSE MODELS OF CANCER, BONE DISEASE, AND LACTATIONK26RR000168 · NCRR · OHIO STATE UNIVERSITY · PI ROSOL, THOMAS J · 2000 to 2004
$547k
HIV Molecular Biology /DNA Vaccine Approaches to AIDSZ01SC010387 · SC · CLINICAL SCIENCES · PI PAVLAKIS, GEORGE N. · 2001 to 2005
–
NCRR NIH HHS K26 RR000168NCRR NIH HHS P51 RR000168NCRR NIH HHS RR00168NIAID NIH HHS R01 AI050421NIAID NIH HHS R01 AI057039NIAID NIH HHS R01-AI057039NIAID NIH HHS R01AI50421
6 · The paper itself

Abstract

A truncating E767stop mutation was introduced into the envelope glycoprotein of simian immunodeficiency virus (SIV) strain SIV239-M5 (moderately sensitive to antibody-mediated neutralization and lacking five sites for N-linked carbohydrate attachment) and strain SIV316 (very sensitive to neutralization, with eight amino acid changes from the neutralization-resistant parental molecular clone, SIV239). The truncating mutation increased Env content in virions, increased infectivity, and decreased sensitivity to antibody-mediated neutralization in both strains. However, the magnitude of the effect on infectivity and neutralization sensitivity differed considerably between the two strains. In the context of strain SIV239-M5, truncation increased Env content in virions approximately 10-fold and infectivity in a reporter cell assay 24-fold. The truncated SIV239-M5 was only slightly more resistant to neutralization by polyclonal monkey sera and by monoclonal antibodies than SIV239-M5 with a full-length envelope glycoprotein. In the context of strain SIV316, truncation increased infectivity a dramatic 480-fold, while envelope content in virions was increased only about 14-fold. This dramatic increase in infectivity cannot be simply explained by the increase in envelope content and is likely due to an increase in inherent infectivity, i.e., infectivity per spike, that results from truncation. The truncated SIV316 was extremely resistant to antibody-mediated neutralization. In fact, it was not neutralized by any of the antibodies tested. When increasing amounts of SIV316 envelope glycoprotein (full length) were provided in trans to SIV316, infectivity was increased and sensitivity to neutralization was decreased, but to nowhere near the degree that was obtained when truncated SIV316 envelope glycoprotein was used. Truncated forms of SIV239 and SIV239-M5 required higher levels of soluble CD4 for inhibition of infection than their nontruncated forms; truncated SIV316 did not. Our results suggest that envelope content in SIV virions, infectivity, and resistance to antibody-mediated neutralization can be increased not only by truncation of the cytoplasmic domain but also by provision of excess envelope in trans. The striking increase in infectivity that results from truncation in the context of SIV316 appears to be due principally to an increase in inherent infectivity per spike.

Indexed as

Antibodies, MonoclonalAntibodies, ViralCD4 AntigensCell LineCodon, NonsenseHumansMembrane GlycoproteinsMutagenesis, Site-DirectedMutationNeutralization TestsProtein Structure, TertiaryRetroviridae ProteinsSimian Immunodeficiency VirusVirionAntibodies, MonoclonalAntibodies, ViralCD4 AntigensCodon, NonsenseMembrane GlycoproteinsRetroviridae ProteinsSIV envelope protein gp41

Identifiers

PMID16160173
PMCPMC1211544
OpenAlexW2000698336

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.